ARTICLE | Company News
Moderna announces pipeline updates in first financial results
March 7, 2019 11:21 PM UTC
In its first quarterly financial results as a public company, Moderna announced its first rare disease mRNA program is heading to the clinic.
Moderna Inc. (NASDAQ:MRNA) said Wednesday that it has submitted an IND for mRNA-3704 to treat methylmalonic acidemia, and the company is preparing to begin a Phase I/II trial. It did not disclose a timeline. It said FDA granted Fast Track designation to the therapy, a liver-specific mRNA targeting the methylmalonyl CoA mutase (MUT) gene...
BCIQ Company Profiles
BCIQ Target Profiles